Eltrekibart
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Eltrekibart
- eltrekibart
- Eltrekibart
- eltrekibart [INN]
- ELTREKIBART [USAN]
- Eltrekibart [WHO-DD]
- eltrekibart inn
- eltrekibart usan
- eltrekibart who dd
- Immunoglobulin G4 [234-proline,de-C-terminal-lysine], anti-(human ELR motif-containing CXC chemokines) (human-Mus musculus monoclonal LY3041658 γ1-chain), disulfide with human-Mus musculus monoclonal LY3041658 κ-chain, dimer
- immunoglobulin g4 234 proline de c terminal lysine anti human elr motif containing cxc chemokines human mus musculus monoclonal ly3041658 γ1 chain disulfide with human mus musculus monoclonal ly3041658 κ chain dimer
- ly 3041658
- LY-3041658
- ly3041658
- Ly3041658
- LY3041658
- CAS registry numbers
- 2484883-56-7
- ChEMBL ID
- CHEMBL5314628
- FDA ingredient codes (UNII)
- WB62WIH13E
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -bart
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition
- Inflammation
- Highest recorded phase
- 1
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
- NCT02896868
- NCT04493502
- NCT06046729
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGASVKVSCKASGYEFTSYWIHWVRQAPGQGLEWMGNISPNSGSANYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGPYSYYPSREYYGSDLWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIYYTSRSVSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCGQNNEWPEVFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 303 $ 303''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 140-214' $ 140''-214''' $ 153-209 $ 153''-209'' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431''
Related records
Trials (7)
- A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- A Study of Eltrekibart (LY3041658) in Healthy Participants
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- A Study of LY3041658 in Adults With Hidradenitis Suppurativa
- A Study of LY3041658 in Healthy Participants
- A Study of LY3041658 in Participants With Skin Diseases
- Safety Study of LY3041658 in Healthy Participants
In development for (3)
- Hidradenitis suppurativa Phase 2
- Psoriasis Phase 1
- Ulcerative colitis Phase 1